Exicure (XCUR)

• Market cap: $7.53M
• 1 day: 5.5%
• 5 days: 10.58%
• 1 month: -16.06%
• 3 months: -30.3%
• 6 months: -70.13%
• Year to date: -79.39%
• 1 year: -77.63%
• 5 years: -99.36%
• 10 years: -99.71%
• Sector: Healthcare
• Industry: Biotechnology

About: Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Employees: 8